{"id":3213,"date":"2024-06-10T11:22:34","date_gmt":"2024-06-10T15:22:34","guid":{"rendered":"https:\/\/cytel.agencyukdev.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/"},"modified":"2024-08-22T05:46:33","modified_gmt":"2024-08-22T09:46:33","slug":"key-elements-and-implications-of-the-draft-eu-jca-implementing-act","status":"publish","type":"perspectives","link":"https:\/\/cytel.agencyukdev.com\/fr\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/","title":{"rendered":"Key Elements and Implications of the Draft EU JCA Implementing Act"},"content":{"rendered":"<p>The draft Implementing Act of the EU Health Technology Assessment Regulation (HTAR) for Joint Clinical Assessments (JCA) of medicinal products \u2014 the first legal definition of the procedural and methodological details for the new EU HTAR JCA \u2014 was published by the European Commission on March 5, 2024, following some delay.<a href=\"#Notes\" rel=\"noopener\">1 <\/a>The draft is currently open for public consultation until April 2, and feedback received will be considered before the European Commission finalizes the Implementation Act.<\/p>\n<p>Here, we delve into the key elements of the Implementing Act and the implications for sponsors.<\/p>\n<p><!--more--><\/p>\n<p>&nbsp;<\/p>\n<h2>Sneak peek into the future: Key elements of the draft Implementing Act<\/h2>\n<ul>\n<li><strong>Article 2<\/strong><\/li>\n<\/ul>\n<p style=\"padding-left: 40px;\">The <a href=\"\/blog\/unravelling-pico-the-pillars-of-the-european-joint-clinical-assessment\" target=\"_blank\" rel=\"noopener\">Population, Intervention, Comparators, and Outcomes (PICO)<\/a> scoping process central to the new EU HTAR is defined under Article 2. When submitting a marketing authorization application to the European Medicines Agency (EMA), sponsors will also provide information to the HTA Secretariat relevant to developing the assessment scope for the JCA of the medicinal product submitted. This information will come from the summary of the product characteristics and clinical overview section of the EMA submission. Notably, sponsors will only be asked for additional information in a meeting or in writing if deemed necessary. This suggests limited engagement in the PICO scoping process, with no apparent option for sponsors to submit PICO proposals or further clarification points in case of strong disagreement with the PICO final document.<\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li><strong>Article 12 <\/strong><\/li>\n<\/ul>\n<p style=\"padding-left: 40px;\">Article 12 confirms previously published tentative timelines. Sponsors will have 90 days from the HTA Secretariat finalizing the assessment scope to submit their <a href=\"\/blog\/real-life-data-sharing-and-eu-joint-clinical-assessments-is-closing-this-chasm-a-mission-impossible\" target=\"_blank\" rel=\"noopener\">JCA<\/a> dossier. Figure 1 summarizes the EU HTAR JCA timelines (bottom) running parallel to the EMA submission process (top). At any point during the preparation of the draft joint clinical assessment and summary reports, sponsors will have seriously tight deadlines to respond to further requests \u2014 between 7 and 30 days to provide further information regarding the data submitted, data analyses, or additional evidence requested by the assessors.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Figure 1:\u00a0Timelines and Preparatory Activities for EU JCA<\/strong><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-4775\" src=\"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Vinals_Sarri_EU_JCA_Fig1.webp\" alt=\"\" width=\"860\" height=\"381\" srcset=\"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Vinals_Sarri_EU_JCA_Fig1.webp 860w, https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Vinals_Sarri_EU_JCA_Fig1-300x133.webp 300w, https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/06\/Vinals_Sarri_EU_JCA_Fig1-473x210.webp 473w\" sizes=\"auto, (max-width: 860px) 100vw, 860px\" \/><\/p>\n<ul>\n<li><strong>Article 16<\/strong><\/li>\n<\/ul>\n<p style=\"padding-left: 40px;\">Article 16 specifically covers potential changes in indications submitted to the EMA and highlights the potential for a new assessment scope being needed in these cases.<\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li><strong>Articles 6\u201310<\/strong><\/li>\n<\/ul>\n<p style=\"padding-left: 40px;\">Articles 6\u201310 outline external stakeholder engagement (e.g., clinical experts, patients, and relevant experts) in the JCA process. Notably, the HTA Secretariat can solicit input from external stakeholders at any stage while developing the assessment scope proposal.<\/p>\n<p>&nbsp;<\/p>\n<p>The draft JCA dossier template, provided as an Annex to the Implementing Act, is heavily based on the structure and content of the dossier in the AMNOG framework in Germany.<a href=\"#Notes\" rel=\"noopener\"><sup>2<\/sup><\/a> Of note, the cut-off date for the literature searches to identify the evidence to be included in the dossier has to be a maximum of 3 months before the submission. Also annexed to the Implementing Act is the template for the JCA report, which remains broad with limited detail.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Implications of the draft Implementing Act for sponsors<\/strong><\/p>\n<p style=\"padding-left: 40px;\">Overall, the draft JCA implementing underscores the following critical points for sponsors:<\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li>Limited opportunity to provide input during the PICO scoping process<\/li>\n<li>Challenging timelines favoring the assessors<\/li>\n<li>Strong need for parallel preparatory activities to meet challenging timelines while creating broad evidentiary packages<\/li>\n<li>Build into strategic development a balance between the risk for additional (and perhaps unnecessary) preparatory activities versus agility to accommodate last-minute requests<\/li>\n<li>Consideration of the EU JCA timelines for local EU national submissions<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>However, there are several remaining unknowns, for example:<\/p>\n<p>&nbsp;<\/p>\n<ul>\n<li>What specific processes and methods will underpin the EU JCA?<\/li>\n<li>\u00a0How to address potential variation in additional local data requests?<\/li>\n<li>What will be the extent of detailed presentation of local data from the 27 EU member states within the EU JCA dossier?<\/li>\n<li>Will there be a potential benefit for sponsors to delay launching in local EU countries if the EU JCA report is not favorable? Should sponsors attempt to submit additional data, if possible?<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Keeping these considerations in mind, how can sponsors best prepare for optimal JCA submissions? Early organizational preparation, stakeholder engagement and methodological readiness will be crucial for preparing timely and robust evidence packages, ensuring prompt EU JCA submissions and successful drug launches. In particular, sponsors should consider how to <strong>COLLABORATE<\/strong> via:<\/p>\n<ul>\n<li><strong>C<\/strong>ross-functional training on EU HTAR and its implications<\/li>\n<li><strong>O<\/strong>utlining global, regional (EU), and local evidentiary needs and methods acceptability criteria<\/li>\n<li><strong>L<\/strong>earning from <a href=\"https:\/\/cytel.agencyukdev.com\/solutions\/rwe-solutions\/real-world-data\/\">real-world data<\/a> (RWD) including common data models and following EU-funded RWD case studies (e.g., DARWIN, SUSTAIN-HTA)<\/li>\n<li><strong>L<\/strong>everaging advanced <a href=\"https:\/\/cytel.agencyukdev.com\/perspectives\/the-case-for-network-meta-interpolation-to-handle-effect-modifiers-in-indirect-treatment-comparisons\/\">indirect treatment comparison<\/a> (ITC) methods (particularly in evidentiary challenging contexts such as reliance on single-arm trial data, surrogate endpoints, indications without\u00a0a dedicated treatment pathway)<a href=\"#Notes\" rel=\"noopener\"><sup>3,4<\/sup><\/a><\/li>\n<li><strong>A<\/strong>nticipating stakeholder involvement for wider EU representation<\/li>\n<li><strong>B<\/strong>uilding on patient involvement and consideration of additional value elements (e.g., equity)<\/li>\n<li><strong>O<\/strong>utlining interdependencies between local and regional evidentiary needs for optimized submissions<\/li>\n<li><strong>R<\/strong>ecognizing commonalities, differences, and gaps in methodological guidance across EU markets\u200b<\/li>\n<li><strong>A<\/strong>ligning EU JCA and local HTA evidence write-ups, where possible<\/li>\n<li><strong>T<\/strong>imely updates on evidence packages and technology value story<\/li>\n<li><strong>E<\/strong>vidence generation risk assessment<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Interested in learning more?<\/strong> <a href=\"https:\/\/cytel.agencyukdev.com\/resource\/eu-jca-preparation-and-hta-regulation\/\">Watch<\/a> the on-demand webinar \u201cFrom EU JCA to Local HTA Submissions: Understanding Commonalities, Differences, and Gaps in Methodological Guidance Across Key EU Markets\u201d hosted by Lydia Vinals and Grammati Sarri.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"color: #102d7b;\"><strong>References<\/strong><\/span><\/p>\n<p><sup>1 <\/sup>European Commission, \u201c<a href=\"https:\/\/ec.europa.eu\/info\/law\/better-regulation\/have-your-say\/initiatives\/13708-Health-technology-assessment-joint-clinical-assessments-of-medicinal-products_en\" target=\"_blank\" rel=\"noopener\">Health technology assessment \u2014 joint clinical assessments of medicinal products<\/a>\u201d [accessed March 7, 2024].<\/p>\n<p><sup>2<\/sup> Gemeinsamer Bundesausschuss, \u201c<a href=\"https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/informationen-fuer-unternehmen\/formulare-und-vorgaben\/\" target=\"_blank\" rel=\"noopener\">Formulare und Vorgaben zum Download \u2013 Anlagen zum 5. Kapitel der Verfahrensordnung<\/a>\u201d\u00a0[accessed March 7, 2024].<\/p>\n<p><sup>3<\/sup> Sarri, G., Rizzo, M., Upadhyaya, S., Paly, V. F., &amp; Hernandez, L. (2024). <a href=\"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0140\" target=\"_blank\" rel=\"noopener\">Navigating the unknown: how to best &#8216;reflect&#8217; standard of care in indications without a dedicated treatment pathway in health technology assessment submissions<\/a>. <em>Journal of comparative effectiveness research, 13<\/em>(2), e230145.<\/p>\n<p><sup>4<\/sup> Appiah, K., Rizzo, M., Sarri, G., &amp; Hernandez, L. (2024). <a href=\"https:\/\/doi.org\/10.57264\/cer-2023-014\" target=\"_blank\" rel=\"noopener\">Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments<\/a>. <em>Journal of comparative effectiveness research, 13<\/em>(2), e230140.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"featured_media":3714,"parent":0,"template":"","meta":{"_acf_changed":false},"tags":[76],"by-topic":[446,431,452],"by-year":[74],"class_list":["post-3213","perspectives","type-perspectives","status-publish","has-post-thumbnail","hentry","tag-blog","by-topic-hta","by-topic-real-world-evidence","by-topic-regulatory-affairs","by-year-74"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Key Elements and Implications of the Draft EU JCA Implementing Act - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us<\/title>\n<meta name=\"description\" content=\"Grammati Sarri and Lydia Vinals discuss key elements of the draft Implementing Act of the EU HTAR JCA of medicinal products and implications for sponsors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Key Elements and Implications of the Draft EU JCA Implementing Act - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"og:description\" content=\"Grammati Sarri and Lydia Vinals discuss key elements of the draft Implementing Act of the EU HTAR JCA of medicinal products and implications for sponsors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/\" \/>\n<meta property=\"og:site_name\" content=\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-22T09:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/iStock-1470900675_abstract.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2337\" \/>\n\t<meta property=\"og:image:height\" content=\"1283\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/\",\"url\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/\",\"name\":\"Key Elements and Implications of the Draft EU JCA Implementing Act - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/iStock-1470900675_abstract.jpg\",\"datePublished\":\"2024-06-10T15:22:34+00:00\",\"dateModified\":\"2024-08-22T09:46:33+00:00\",\"description\":\"Grammati Sarri and Lydia Vinals discuss key elements of the draft Implementing Act of the EU HTAR JCA of medicinal products and implications for sponsors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/iStock-1470900675_abstract.jpg\",\"contentUrl\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/iStock-1470900675_abstract.jpg\",\"width\":2337,\"height\":1283,\"caption\":\"abstract vector background with hexagons. 3d design\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cytel.com\\\/perspectives\\\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Key Elements and Implications of the Draft EU JCA Implementing Act\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/#website\",\"url\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/\",\"name\":\"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us\",\"description\":\"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cytel.agencyukdev.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Key Elements and Implications of the Draft EU JCA Implementing Act - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Grammati Sarri and Lydia Vinals discuss key elements of the draft Implementing Act of the EU HTAR JCA of medicinal products and implications for sponsors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/","og_locale":"fr_FR","og_type":"article","og_title":"Key Elements and Implications of the Draft EU JCA Implementing Act - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","og_description":"Grammati Sarri and Lydia Vinals discuss key elements of the draft Implementing Act of the EU HTAR JCA of medicinal products and implications for sponsors.","og_url":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/","og_site_name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","article_modified_time":"2024-08-22T09:46:33+00:00","og_image":[{"width":2337,"height":1283,"url":"https:\/\/www.cytel.com\/wp-content\/uploads\/2024\/05\/iStock-1470900675_abstract.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/","url":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/","name":"Key Elements and Implications of the Draft EU JCA Implementing Act - Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","isPartOf":{"@id":"https:\/\/cytel.agencyukdev.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/#primaryimage"},"image":{"@id":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/#primaryimage"},"thumbnailUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/iStock-1470900675_abstract.jpg","datePublished":"2024-06-10T15:22:34+00:00","dateModified":"2024-08-22T09:46:33+00:00","description":"Grammati Sarri and Lydia Vinals discuss key elements of the draft Implementing Act of the EU HTAR JCA of medicinal products and implications for sponsors.","breadcrumb":{"@id":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/#primaryimage","url":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/iStock-1470900675_abstract.jpg","contentUrl":"https:\/\/cytel.agencyukdev.com\/wp-content\/uploads\/2024\/05\/iStock-1470900675_abstract.jpg","width":2337,"height":1283,"caption":"abstract vector background with hexagons. 3d design"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cytel.com\/perspectives\/key-elements-and-implications-of-the-draft-eu-jca-implementing-act\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/cytel.agencyukdev.com\/"},{"@type":"ListItem","position":2,"name":"Key Elements and Implications of the Draft EU JCA Implementing Act"}]},{"@type":"WebSite","@id":"https:\/\/cytel.agencyukdev.com\/#website","url":"https:\/\/cytel.agencyukdev.com\/","name":"Clinical Trial Software &amp; Data Analysis | Cytel | Contact Us","description":"Innovative Trial Design. Cytel is the largest provider of statistical software and advanced analytics for clinical trial design and execution.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cytel.agencyukdev.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives\/3213","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/perspectives"}],"about":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/types\/perspectives"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media\/3714"}],"wp:attachment":[{"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/media?parent=3213"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/tags?post=3213"},{"taxonomy":"by-topic","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-topic?post=3213"},{"taxonomy":"by-year","embeddable":true,"href":"https:\/\/cytel.agencyukdev.com\/fr\/wp-json\/wp\/v2\/by-year?post=3213"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}